论文部分内容阅读
应用上海生物制品研究所1980年研制成的人凝血因子Ⅷ浓制剂,对10例重,中型血友病甲患者进行治疗。初步临床观察说明(1)该制剂的安全性佳,无过敏、热源反应及其它付作用;(2)7例关节、肌肉型出血在一次输入适当剂量后即可使Ⅷ:C上升至止血水平,临床均呈显效,一例颅内出血,一例严重消化道出血患者经过输因子Ⅷ浓制剂抢救,病情转危为安,一例左颌骨囊肿摘除术者在因子Ⅷ浓制剂保护的情况下安全渡过手术。(3)该制剂的半寿期介于4～12小时,临床一般可间隔8～12小时给药,所需使用的剂量可按每单位/公斤体重提高Ⅷ:C2.63%计算。该制剂尤其适用于需在短期内迅速提高Ⅷ:C水平,如颅内出血、大手术的抢救。推广应用人凝血因子Ⅷ浓制剂对提高血友病甲的疗效将具有重要意义。
Application of Shanghai Institute of Biological Products developed in 1980, the human factor Ⅷ coagulation factor, 10 patients with severe, moderate hemophilia A patients were treated. Preliminary clinical observation shows that: (1) The preparation is safe, non-allergic, heat-source reaction and other side effects; (2) 7 cases of joint and muscle hemorrhage can make Ⅷ: C rise to the level of hemostasis , Clinical were markedly effective, one case of intracranial hemorrhage, a case of severe gastrointestinal bleeding in patients with intravenous infusion of factor VIII concentrated rescue, the condition turned dangerous, a case of left mandibular cyst exhumation surgery in the case of factor VIII concentration of safeguarded surgery. (3) The half-life of the preparation ranges from 4 to 12 hours. Generally, it can be administered in intervals of 8 to 12 hours. The required dosage can be calculated as Ⅷ: C2.63% per unit weight / kg of body weight. This preparation is especially suitable for rapidly increasing Ⅷ: C levels in the short term, such as intracranial hemorrhage and major surgery. Promote the application of human coagulation factor Ⅷ concentrated preparations to improve the efficacy of hemophilia A will be of great significance.